Marinol, a registered trademark of Unimed Pharmaceuticals, Inc. is the commercial name for a product containing dronabinol, an analog of Δ9-tetrahydrocannabinol (THC). THC is a naturally occurring component in cannabis.
Marinol is an FDA-approved cannabinoid and is prescribed as an appetite stimulant, primarily for AIDS, chemotherapy and gastric bypass patients. Compare Sativex, a mouth spray for neuropathic pain of multiple sclerosis sufferers approved for use in Canada and in the US as of 2006. While Marinol can serve as an anti-emitic and appetite booster, its immunomodulative effect should be taken into account in the treatment of any compromised immune condition.